Skip to main content
Back to feed
MarketsSingle-sourceLow
2.1

Ascelia Pharma eliminates CFO position following FDA rejection

Ascelia Pharma is restructuring its executive leadership by removing the CFO role to reduce operational costs. This follows a significant decline in share price triggered by an unfavorable FDA regulatory decision regarding its drug candidate.

Dagens Industri3 days agoSE, USCredibility 27%View source

Score Breakdown

Mosaic Score2.1
Confidence0.9
Significance0.1
Source credibility0.3

Intelligence Tags

#pharma#restructuring#cfo#fda#equity

Entities

countrycountry
Source

Related signals

8 found